Total Payments
$183,987
2024 Payments
$17,363
Companies
14
Transactions
204
Medicare Patients
5,903
Medicare Billing
$1.7M
Payment Breakdown by Category
Research$75,979 (41.3%)
Other$50,685 (27.5%)
Consulting$34,223 (18.6%)
Travel$21,313 (11.6%)
Food & Beverage$1,775 (1.0%)
Education$13.06 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $75,979 | 69 | 41.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45,720 | 39 | 24.8% |
| Consulting Fee | $34,223 | 14 | 18.6% |
| Travel and Lodging | $21,313 | 27 | 11.6% |
| Honoraria | $3,350 | 6 | 1.8% |
| Food and Beverage | $1,775 | 29 | 1.0% |
| Long term medical supply or device loan | $1,615 | 18 | 0.9% |
| Education | $13.06 | 2 | 0.0% |
Payments by Type
General
$108,008
135 transactions
Research
$75,979
69 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $148,213 | 136 | $0 (2024) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $8,419 | 23 | $0 (2023) |
| Daiichi Sankyo Inc. | $7,937 | 9 | $0 (2020) |
| GENZYME CORPORATION | $4,010 | 1 | $0 (2021) |
| PUMA BIOTECHNOLOGY, INC. | $3,618 | 5 | $0 (2021) |
| Amgen Inc. | $3,385 | 8 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $2,085 | 3 | $0 (2021) |
| Athenex Pharmaceutical Division, LLC | $1,850 | 5 | $0 (2020) |
| Eli Lilly and Company | $1,229 | 1 | $0 (2021) |
| TerSera Therapeutics LLC | $1,093 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,363 | 13 | PFIZER INC. ($17,270) |
| 2023 | $24,974 | 14 | PFIZER INC. ($24,704) |
| 2022 | $30,579 | 28 | PFIZER INC. ($30,246) |
| 2021 | $32,620 | 49 | PFIZER INC. ($23,240) |
| 2020 | $24,136 | 22 | PFIZER INC. ($10,910) |
| 2019 | $18,567 | 31 | PFIZER INC. ($13,992) |
| 2018 | $25,627 | 29 | PFIZER INC. ($18,822) |
| 2017 | $10,122 | 18 | PFIZER INC. ($9,029) |
All Payment Transactions
204 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | PFIZER INC. | IBRANCE (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: IBRANCE CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/17/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 08/06/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 08/05/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 07/18/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 05/16/2024 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 05/03/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: ONCOLOGY | ||||||
| 03/08/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: ONCOLOGY | ||||||
| 02/06/2024 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 01/29/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: ONCOLOGY | ||||||
| 01/12/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2023 | PFIZER INC. | — | Travel and Lodging | Cash or cash equivalent | $1,311.24 | General |
| 12/04/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2023 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 10/24/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $11,785.80 | General |
| 10/24/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $1,918.24 | General |
| 10/24/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $288.90 | General |
| 07/10/2023 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 06/23/2023 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 05/31/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| 05/10/2023 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 03/23/2023 | PFIZER INC. | IBRANCE (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 03/06/2023 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $1,400.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $40,930 | 40 |
| TALAZOPARIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $30,620 | 27 |
| IBRANCE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $1,229 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 15 | 497 | 1,249 | $140,911 | $23,782 |
| 2021 | 59 | 2,761 | 46,820 | $3.4M | $744,964 |
| 2020 | 60 | 2,645 | 47,222 | $3.8M | $946,674 |
Total Patients
5,903
Total Services
95,291
Medicare Billing
$1.7M
Procedure Codes
134
All Medicare Procedures & Services
134 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 15 | 39 | $6,240 | $6,234 | 99.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 44 | 54 | $38,178 | $5,728 | 15.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 72 | 86 | $31,648 | $5,025 | 15.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 74 | 126 | $8,064 | $1,328 | 16.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 14 | $6,944 | $1,036 | 14.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 73 | 125 | $4,500 | $969.25 | 21.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 25 | 66 | $7,128 | $845.33 | 11.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 12 | 16 | $5,504 | $836.69 | 15.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 17 | 28 | $4,396 | $625.00 | 14.2% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2022 | 12 | 22 | $2,816 | $457.40 | 16.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 78 | 134 | $2,680 | $401.07 | 15.0% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2022 | 15 | 190 | $21,660 | $130.34 | 0.6% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2022 | 14 | 15 | $735.00 | $126.42 | 17.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 22 | 320 | $320.00 | $29.94 | 9.4% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2022 | 12 | 14 | $98.00 | $11.05 | 11.3% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2021 | 21 | 6,200 | $779,000 | $255,264 | 32.8% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2021 | 15 | 4,760 | $335,820 | $109,427 | 32.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 65 | 428 | $68,480 | $68,802 | 100.5% |
| 78815 | Nuclear medicine study with ct imaging skull base to mid-thigh | Office | 2021 | 29 | 36 | $169,872 | $43,944 | 25.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 145 | 374 | $137,632 | $37,482 | 27.2% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2021 | 11 | 1,250 | $305,000 | $36,287 | 11.9% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 188 | 274 | $193,718 | $33,178 | 17.1% |
| J2505 | Injection, pegfilgrastim, 6 mg | Office | 2021 | 11 | 13 | $204,126 | $27,093 | 13.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 12 | 1,440 | $77,760 | $23,376 | 30.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 40 | 82 | $40,672 | $11,978 | 29.4% |
About Dr. Joanne Blum, M.D
Dr. Joanne Blum, M.D is a Hematology & Oncology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285676411.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joanne Blum, M.D has received a total of $183,987 in payments from pharmaceutical and medical device companies, with $17,363 received in 2024. These payments were reported across 204 transactions from 14 companies. The most common payment nature is "" ($75,979).
As a Medicare-enrolled provider, Blum has provided services to 5,903 Medicare beneficiaries, totaling 95,291 services with total Medicare billing of $1.7M. Data is available for 3 years (2020–2022), covering 134 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Dallas, TX
- Active Since 06/12/2006
- Last Updated 10/08/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1285676411
Products in Payments
- TALZENNA (Drug) $54,330
- IBRANCE (Drug) $50,976
- KISQALI (Drug) $8,169
- Enhertu (Drug) $7,937
- NERLYNX (Drug) $3,606
- XGEVA (Biological) $3,371
- Oral Paclitaxel (Drug) $1,500
- ZOLADEX (Drug) $1,093
- Trodelvy (Drug) $1,000
- EPKINLY (Drug) $76.80
- IMBRUVICA (Drug) $35.44
- VENCLEXTA (Drug) $23.97
- Neulasta (Biological) $13.89
- LYNPARZA (Drug) $13.61
- Nerlynx (Drug) $11.69
- BOSULIF (Drug) $1.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Dallas
Dr. Christopher Maisel, Md, MD
Hematology & Oncology — Payments: $884,793
Hematology & Oncology $884,793
Dr. Houston Holmes, M.d, M.D
Hematology & Oncology — Payments: $261,905
Hematology & Oncology $261,905
Dr. Kartik Konduri, Md, MD
Hematology & Oncology — Payments: $253,193
Hematology & Oncology $253,193
Dr. Farrukh Awan, M.d., M.s, M.D., M.S
Hematology & Oncology — Payments: $184,107
Hematology & Oncology $184,107
Joan Schiller, Md, MD
Hematology & Oncology — Payments: $174,115
Hematology & Oncology $174,115
Dr. Carlos Becerra, M.d, M.D
Hematology & Oncology — Payments: $161,287
Hematology & Oncology $161,287